Response adaptive randomisation in clinical trials: Current practice, gaps and future directions
Statistical Methods in Medical Research · 2025
DOI: 10.1177/09622802251348183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistical Methods in Medical Research, 2025. Verfasst von Isabelle Wilson und 4 weiteren Autor:innen. Beteiligte Einrichtung: SCHARR, The University of Sheffield, UK. Hauptthemen laut MEDLINE: Research Design, Randomized Controlled Trials as Topic, Adaptive Clinical Trials as Topic, Clinical Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Pre-doctoral Fellowship.
Abstract (Originalsprache)
Introduction
Adaptive designs (ADs) offer clinical trials flexibility to modify design aspects based on accumulating interim data. Response adaptive randomisation (RAR) adjusts treatment allocation according to interim results, favouring promising treatments. Despite scientific appeal, RAR adoption lags behind other ADs. Understanding methods and applications could provide insights and resources and reveal future research needs. This study examines RAR application, trial results and achieved benefits, reporting gaps, statistical tools and concerns, while highlighting examples of effective practices.
Methods
RAR trials with comparative efficacy, effectiveness or safety objectives, classified at least phase I/II, were identified via statistical literature, trial registries, statistical resources and researcher-knowledge. Search spanned until October 2023, including results until February 2024. Analysis was descriptive and narrative.
Results
From 652 articles/trials screened, 65 planned RAR trials (11 platform trials) were identified, beginning in 1985 and gradually increasing through to 2023. Most trials were in oncology (25%) and drug-treatments (80%), with 63% led by US teams. Predominantly Phase II (62%) and multi-arm (63%), 85% used Bayesian methods, testing superiority hypotheses (86%). Binary outcomes appeared in 55%, with a median observation of 56 days. Bayesian RAR algorithms were applied in 83%. However, 71% of all trials lacked clear details on statistical implementation. Subgroup-level RAR was seen in 23% of trials. Allocation was restricted in 51%, and 88% was included a burn-in period. Most trials (85%) planned RAR alongside other adaptations. Of trials with results, 92% used RAR, but over 50% inadequately reported allocation changes. A mean 22% reduction in sample size was seen, with none over-allocating to ineffective arms.
Conclusion
RAR has shown benefits in conditions like sepsis, COVID-19 and cancer, enhancing effective treatment allocation and saving resources. However, complexity, costs and simulation need limit wider adoption. This review highlights RAR's benefits and suggests enhancing statistical tools to encourage wider adoption in clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SCHARR, The University of Sheffield, UK.
- Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
- Department of Mathematics and Statistics, University of Reading, UK.
ORCID-Profile: Isabelle Wilson, Steven Julious, Christina Yap, Susan Todd, Munyaradzi Dimairo
Förderung
- NIHR Pre-doctoral Fellowship
Zitieren
APA
Wilson, I., Julious, S., Yap, C., Todd, S., & Dimairo, M. (2025). Response adaptive randomisation in clinical trials: Current practice, gaps and future directions. Statistical Methods in Medical Research. https://doi.org/10.1177/09622802251348183
Vancouver
Wilson I, Julious S, Yap C, Todd S, Dimairo M. Response adaptive randomisation in clinical trials: Current practice, gaps and future directions. Statistical Methods in Medical Research. 2025. doi:10.1177/09622802251348183
BibTeX
@article{Wilson2025,
author = {Wilson, Isabelle and Julious, Steven and Yap, Christina and Todd, Susan and Dimairo, Munyaradzi},
title = {Response adaptive randomisation in clinical trials: Current practice, gaps and future directions},
journal = {Statistical Methods in Medical Research},
year = {2025},
doi = {10.1177/09622802251348183}
}
EUVIMED